Extended Data Fig. 6: Effects of αPD1-mEry in pB3 tumor-bearing mice.
a, Proportion of MDSCs in the BM, spleens, PB, and LN of two groups of mice, analyzed by flow cytometry: tumor-free (n = 5 mice) and pB3 tumor-bearing mice (n = 6 mice) with tumors of approximately 500 mm3 in size. Relative fold change in the proportion of MDSCs was calculated by normalizing the results to the tumor-free mice. b, Quantification of αPD1-mEry density in various tissues from pB3 tumor-bearing C57BL/6-hPD1 mice 4 h after injection (n = 3 mice). c, Bilateral flank pB3 tumor-bearing C57BL/6-hPD1 mice were treated with IgG4-mEry, IgG4-mEry plus anti-PD1 or αPD1-mEry twice a week once tumors reached ~50 mm3. Tumor growth was recorded (n = 5 mice per group). Data are presented as mean ± s.e.m. Statistical significance was determined using a two-tailed unpaired t-test (a) or two-way ANOVA with Tukey’s multiple comparisons test (c).
